Randomized Controlled Trial of a Strategic Disclosure Intervention for Suicide Attempt Survivors
While suicide prevention depends on people disclosing suicidal thoughts and behaviors in order to get help, those who talk about their suicidality also face negative responses from the people who they tell. The investigators will conduct a randomized controlled trial of a peer-led strategic disclosure intervention for suicide attempt survivors (The To Share or Not to Share Program; called 2Share). This study evaluates the impact of the intervention on suicidal thoughts and behaviors, depression, stigma, disclosure behaviors, and psychosocial outcomes.
Impact of High Deductible Health Plans on Patients With Bipolar Disorder
Using eleven years (2004-2014) of claims data from the largest US commercial health insurer, the investigators will assess the impact of switching into high-deductible health plans (HDHPs) on outcomes for patients with bipolar disorder. Patient subgroups will include patients with and without high medication cost-sharing and vulnerable populations (racial/ethnic minorities, poor, rural, major comorbidities). Interviews with patients and caregivers recruited through a major advocacy group will provide further insights into the policy issues with real-life experiences.
100 Clinical Results associated with Depression & Bipolar Support Alliance
0 Patents (Medical) associated with Depression & Bipolar Support Alliance
DUBLIN--(
BUSINESS WIRE
)--The
"Depression Treatment Market"
report has been added to
ResearchAndMarkets.com's
offering.
A recent market study published on the depression treatment market offers a global industry analysis for 2012-2021 and an opportunity assessment for 2022-2032. The report consists of a comprehensive assessment of the most important market dynamics.
On conducting thorough research on the historical as well as current growth parameters of the depression treatment market, growth prospects of the market are obtained with maximum precision.
The report features unique and salient factors that may make a huge impact on the development of the depression treatment market during the forecast period. It can help market players modify their manufacturing and marketing strategies to envisage maximum growth in this market in the coming years.
The report provides detailed information about the current and future growth prospects of the depression treatment market in the most comprehensive way for a better understanding of readers.
Companies Mentioned
Viatris (Mylan Pharmaceuticals Inc.)
Sunovian Pharmaceuticals
AbbVie Inc. (Allergan Inc.)
Jubilant Generics Limited
Sanis Health Inc.
Abbott Laboratories
Aurobindo Pharma
Torrent Pharmaceuticals
Teva Pharmaceuticals
Sun Pharmaceuticals
(Apotex Holdings Inc.) Apotex Corporation
Alembic Pharmaceuticals Limited
Pfizer Inc.
Cardinal Health
Hikma Pharmaceuticals
Zydus Lifesciences (Cadila)
Cipla Ltd
Dr. Reddy's Laboratories
Merck & Co.
Eli Lily & Co
GlaxoSmithKline
Takeda Pharmaceuticals
BrainsWay Ltd.
Nexstim Plc
Magstim Ltd.
Neuronetics Inc.
Salience TMS Neuro Solutions
MagVenture
MAG & More GmbH
Neurosoft Ltd.
Key Segments of the Depression treatment Market
This study on the depression treatment market offers information divided into four important segments - products, disease, distribution channel and region.
This report offers comprehensive data and information about the important market dynamics and growth parameters associated with these categories.
By Products
Drugs
Selective Serotonin Reuptake Inhibitors (SSRIs)
Citalopram
Escitalopram
Fluoxetine
Fluvoxamine
Paroxetine
Sertraline
Selective Norepinephrine Reuptake Inhibitors (SNRIs)
Desvenlafaxine succinate
Duloxetine
Levomilnacipran
Venlafaxine
Bupropion
Mirtazapine
Monoamine oxidase inhibitors (MAOIs)
Phenelzine
Tranylcypromine
Antipsychotics
Lithium carbonate
Aripiprazole
Brexipiprazole
Quetiapine
Trazodone
Others
TMS Devices
rTMS Devices
dTMS Devices
By Disease
Major Depression
Persistent Depressive Disorder
Bipolar Disorder
Seasonal Affective Disorder (SAD)
Postpartum Depression
Premenstrual Dysphoric Disorder (PDD)
Situational Depression
Atypical Depression
Treatment-Resistant Depression
By Distribution Channel
Hospitals
Retail Pharmacies
Drug Stores
e-commerce
Specialty Clinics
Region
North America
Latin America
Europe
East Asia
South Asia
Oceania
Middle East and Africa (MEA)
For more information about this report visit
https://www.researchandmarkets.com/r/2h2zat
100 Deals associated with Depression & Bipolar Support Alliance
100 Translational Medicine associated with Depression & Bipolar Support Alliance